Develops placenta-based cell therapies for osteoarthritis and COVID-19.
Jun 2026Revenue $1.02M/yrExpenses $26.0M/yr
No trendCash runway ≈ 2 months from Jun 2026
Figures by year
When will Pluri be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $1.02M and expenses $26.0M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Jun 2026 | $1.02M | $26.0M | −$24.9M |
| Jun 2025 | $1.34M | $23.5M | −$22.2M |
| Jun 2024 | $326K | $22.5M | −$22.2M |
| Jun 2023 | $287K | $27.5M | −$27.2M |
| Jun 2022 | $234K | $41.8M | −$41.6M |
| Jun 2020 | $23.0K | $29.5M | −$29.5M |
| Jun 2019 | $54.0K | $35.6M | −$35.5M |
| Jun 2018 | $50.0K | $33.8M | −$33.7M |
| Jun 2016 | $2.85M | $26.2M | −$23.3M |
| Jun 2015 | $379K | $25.6M | −$25.3M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.